Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow OmniAb, Inc.

Get SEC filing alerts via email and in your feed for OmniAb, Inc.

OABI OABIW

OmniAb, Inc.

About OmniAb, Inc.

OmniAb, Inc. licenses advanced antibody discovery technologies utilizing genetically engineered transgenic animals and AI-driven screening platforms. Its core offerings include diverse fully human antibody repertoires, high-throughput B cell screening, and bispecific antibody platforms. Serving pharmaceutical, biotech, and academic clients worldwide, OmniAb accelerates therapeutic development across multiple modalities, including antibodies, bispecifics, and ion channel targets, leveraging proprietary animal models and computational tools for efficient, high-quality drug candidate identification.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from OmniAb, Inc.

1
1
OmniAb, Inc. OmniAb Reports 247% Revenue Increase to $14.4 Million in Latest Quarter

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
OmniAb, Inc. OmniAb Reports $18.7 Million Revenue Decline and $64.8 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
OmniAb, Inc. OmniAb Reports 46% Revenue Decline in Q3 2025, Net Loss of $16.53 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
OmniAb, Inc. OmniAb Reports 49% Revenue Decline and Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
OmniAb, Inc. OmniAb Reports 9% Revenue Growth to $4.154 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
OmniAb, Inc. OmniAb Reports $26.4 Million Revenue for Fiscal Year 2024, 23% Decrease from 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
OmniAb, Inc. OmniAb Reports 24% Revenue Decline in Q3 2024, Net Loss Widens

Via official filing (AI summary) | over 1 year ago | 0 comments